Clinical Advances in Hematology & OncologyArtificial Intelligence in Prostate Cancer Diagnosis and Management: State-of-the-Art Approaches and Emerging Innovations

🎓 Expert Commentary / Peer Perspective

AI is being evaluated across prostate cancer imaging, pathology, risk stratification, surgery, and radiation oncology. Several platforms have demonstrated diagnostic accuracy approaching specialist performance, while others are being incorporated into prognostic and treatment-selection workflows.

Clinical Considerations

• MRI interpretation models have shown performance comparable to expert radiologists.
• Digital pathology platforms may reduce workload while maintaining diagnostic sensitivity.
• AI-derived prognostic tools are beginning to appear in NCCN-supported workflows.
• Most evidence remains retrospective and requires prospective validation.
• Concerns remain regarding bias, reproducibility, and regulatory oversight.

Practice Applications

• AI currently serves as decision support rather than a replacement for clinician judgment.
• Pathology and imaging workflows may be the most immediate areas for implementation.
• Prospective outcome-based validation remains necessary before broader adoption.